

Effective January 1, 2026

NOTICE TO HOLDERS OF TRUST CLAIMS

PLEASE TAKE NOTICE that pursuant to the Sixth Amendment to the First Amended United Gilsonite Laboratories Asbestos Personal Injury Trust Distribution Procedures, adopted effective September 24, 2024, the Trust shall annually increase the Scheduled Value, Average Value and Maximum Value amounts proportionately by 1.75% per annum for the compensable Disease Levels as set forth in the First Amended United Gilsonite Laboratories Asbestos Personal Injury Trust Distribution Procedures (as amended, the “TDP”).

Pursuant to Sections 5.2(a)(3) and 5.2(b)(3) of the TDP, as amended, the Trustee has increased the Scheduled Values, Average Values, and Maximum Values for the compensable Disease Levels set forth in Section 5.2(b)(3), to increase the amounts by 1.75%.

Accordingly, please take notice that the below adjusted Scheduled Values, Average Values, and Maximum Values for claims involving Disease Levels I – VIII shall apply to all offers made by the Trust from the date of this Notice. For the avoidance of doubt, the adjusted Scheduled Values, Average Values, and Maximum Values do not trigger supplemental payments under Section 4.3 of the TDP.

Scheduled Disease	Scheduled Value	Average Value	Maximum Value
Mesothelioma (Level VIII)	\$259,614	\$292,067	\$519,231
Lung Cancer 1 (Level VII)	\$27,260	\$29,206	\$38,942
Lung Cancer 2 (Level VI)	N/A	\$15,576	\$20,120
Other Cancer (Level V)	\$11,682	\$11,682	\$11,682
Severe Asbestosis (Level IV)	\$15,576	\$16,227	\$19,471
Asbestosis/Pleural Disease (Level III)	\$1,947	\$1,947	\$1,947
Asbestosis/Pleural Disease (Level II)	\$1,169	\$1,169	\$1,169
Other Asbestos Disease (Level I)	\$0	\$0	\$0